Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s):  MEDXF

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.


TSX:MDP - Post by User

Bullboard Posts
Post by TheRock07on Jul 25, 2016 5:13pm
216 Views
Post# 25082920

Options Price Cap off..Ready to rumble

Options Price Cap off..Ready to rumble

 

Pediapharm grants options, issues shares for bonuses

 

2016-07-25 15:55 ET - News Release

 

Mr. Sylvain Chretien reports

PEDIAPHARM ANNOUNCES GRANT OF STOCK OPTIONS AND ISSUANCE OF SHARES FOR SERVICES

Pediapharm Inc.'s board of directors has approved the grant of 2,375,000 stock options to certain directors, officers and employees of the corporation. The options were issued with an exercise price of 30 cents per share and have a term of 10 years. In addition, the options have varied vesting provisions such that they vest either over two years or four years. The board has also approved the grant of 100,000 stock options to Direct Financial Strategies and Communications Inc. at an exercise price of 30 cents per share with a term of two years. These options will vest over a 12-month period at a rate of 25 per cent per quarter. 

The option grants are subject to regulatory and TSX Venture Exchange approval. 

The board has also approved the payment of bonuses to certain officers of the corporation for their contribution during the 12 months ended March 31, 2016. A portion of the bonuses are payable in cash, and the balance shall be payable through the issuance of an aggregate of 196,665 common shares of the corporation at a deemed price of 30 cents per share. 

The common shares will be subject to a four-month hold period under applicable Canadian securities laws ending four months and a day after the date of issue. 

The issuance of common shares for services is subject to the acceptance of the TSX Venture Exchange. 

© 2016 Canjex Publishing Ltd. All rights reserved.

Bullboard Posts